Norway, Dec. 4 -- Thor Medical ASA, a leading emerging supplier of alpha-emitters for next-generation precision cancer treatment, and RadioMedix, Inc., a U.S. based clinical-stage biotechnology company focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring and cancer therapy, have entered into a five-year frame agreement for the supply of thorium-228 (Th-228). The supply of Th-228 will start in 2026, with volumes scaling with increased production at Thor Medical's AlphaOne.RadioMedix will use the Th-228 supplied by Thor Medical as a precursor for the manufacturing of lead-212 (Pb-212) in its development pipeline, and to leverage the company's RAHA-100 Pb-212 generator, designed to increase the availability of Pb-212 f...